
# **QV** Equities Investor Update

October 2019



## **QV Equities Limited**

☐ Listed 22 August 2014

Managed by Investors Mutual

☐ Focused on Ex-20 stocks

■ Experienced Board with independent majority

☐ Focus on long-term capital growth & income



#### Investor needs:

Capital preservation

☐ Reasonable capital growth

■ Income focused



#### **Investment Philosophy: focus on quality**

We seek to buy and own:

Companies with a competitive advantage,

with recurring earnings,

run by capable management,

that can grow,

.....at a reasonable price.



## Global economy

- ☐ US economic growth in mature phase
- ☐ China slowing as trade war impacts
- Eurozone economies meandering

- Emerging economies relatively stable
- .....global growth outlook slowing



## Australian economy


- House prices plateauing
- Residential construction slowing
- Employment strong -> low wage growth
- Consumer spending slowing
- Prolonged drought impacting several sectors
- Infrastructure spending continues
- .....fiscal stimulus and record low interest rates supporting the economy



## Bond yields – Germany



## Bond yields – Germany vs US





## Bond yields – Germany vs US vs Australia





#### ASX300 & Dow Jones



# A challenging operating environment...

■ Rising competition

☐ Higher input prices

☐ Regulatory changes

■ Slowing economy



# Sectors – major changes occurring.....

Retail
Media
Telecommunications
Utilities
Manufacturing
Wagering
Banking



#### Other sectors.....

Healthcare

REITs

Resources

Casinos/lotteries

Infrastructure

☐ Consumer Staples

□ I.T.



# IML positioning - focusing on company specifics

Company specific initiatives – growth through the cycle			
Cost-outs →	Tabcorp		
Acquisitions ->	Amcor, Sonic Healthcare, Steadfast		
Contracted growth→	Shopping Centres Australasia		
Market share gains→	Orica, GWA		
Restructuring ->	Crown Resorts		



# QVE's best performing stocks for 2019

Best performers Aurizon Ruralco Steadfast Genesis Energy Orica



# **Disappointing performers**

☐ Clydesdale Bank

☐ Pact Group

■ Mayne Pharma



## Performance & NTA – as at 30 September 2019

NET TANGIBLE ASSETS (NTA)*	QVE-ASX
NTA before tax	\$1.13
NTA after tax	\$1.11

\*The before and after tax NTA numbers relate to the provision for tax on net profit in addition to deferred tax on the un-realised gains in the Company's investment portfolio. The Company is a long term investor and does not intend disposing of its total portfolio. Under current Accounting standards, the Company is required to provide for tax on any gains that might arise on such a theoretical disposal, after utilisation of brought forward losses. All figures are unaudited and approximate.

PERFORMANCE*	QVE's NTA (pre tax)	QVE's NTA (after tax)	BENCHMARK
1 Month	+0.9%	+1.0%	+1.5%
3 Months	+0.1%	+0.5%	+4.6%
6 Months	+2.0%	+1.8%	+11.5%
1 Year	-0.1%	+0.5%	+11.0%
Since Inception Total Return p.a	+7.1%	+6.1%	+11.4%

The above returns are after fees and assumes all declared dividends are reinvested and excludes tax paid for pre-tax NTA. Past performance is not indicative of future performance.



Source: QVE NTA as at 30 September 2019

## IML's portfolio lagging over recent periods

"Momentum" based market


■ Valuations stretched in some sectors

☐ Industrials sector lagging the Resources sector

- ☐ Significant gains in momentum/concept stocks
- ☐ A few disappointing performers in the portfolio



## **QVE: Performance since inception by Financial Years**




<sup>\*</sup>Returns are from inception date 22 August 2014
Source: QVE NTA announcements; 22 August 2014-30 Sept 2019
The above returns are after fees and assumes all declared dividends are reinvested and excludes tax paid from pre tax NTA. Past performance is not



indicative of future performance.

#### **Historical Dividends to QVE Shareholders**





#### 'Growth' stocks on consensus numbers

	FY2020 PE	FY2021 PE
WTC	138.8x	100.2x
APT	390.5x	100.2x
XRO	467.6x	131.8x
PME	158.4x	118.5x
NAN	160.8x	90.9x




#### 'Growth' stocks on consensus numbers

	FY2020 PE	FY2021 PE
WTC	138.8x	100.2x
APT	390.5x	100.2x
XRO	467.6x	131.8x
PME	158.4x	118.5x
NAN	160.8x	90.9x

Market Cap (\$bn)		
12.1		
8.4		
9.6		
3.5		
2.1		



## Australia's growth stocks are the most expensive in the world





#### **REIT's sector**

☐Good quality, recurring earnings

□Long WALE


□ Low debt/gearing levels

☐ Price to NTA



#### Mirvac

#### \$/NTA



# Stocks with realistic valuations

	FY2020 PE	FY2021 PE
AMC	16.1x	14.9x
NEC	15.1x	14.2x
EVT	18.0x	16.9x
SKC	16.5x	15.8x
PGH	10.4x	9.6x
CTX	12.6x	11.7x




## Stocks with realistic valuations

	FY2020 PE	FY2021 PE
AMC	16.1x	14.9x
NEC	15.1x	14.2x
EVT	18.0x	16.9x
SKC	16.5x	15.8x
PGH	10.4x	9.6x
CTX	12.6x	11.7x

Market Cap (\$bn)		
15.5		
3.4		
2.0		
2.5		
0.8		
6.2		



#### Australia's Non-Bank Industrials at record levels





# Buys for the last 12 months

New stocks	Added to the portfolio
Nine Entertainment	Tabcorp
Origin Energy	Link Administration
Sydney Airport	



#### Sells for the last 12 months

Exit	Trimmed
IPH	Ansell
Abacus Property	Steadfast
Contact Energy	Hotel Property Investments
	AGL
	Spark Infrastructure
	Fletcher Building



## **Clydesdale Bank**



■Established UK retail bank

■ Demerged from NAB

■£60.4bn mortgages\*

■£62.8bn customer deposits\*



# Clydesdale Bank – Factors impacting performance



PPI provisions

☐ Retail competition intensified

■ Brexit uncertainty



## Clydesdale Bank- Why are we still holding/adding to?



PPI scheme closed

☐ Trading at 0.4x book and 5x PE

☐ Virgin synergies still to come through



#### **Pact Group**

PACT

- ☐ Largest manufacturer of rigid plastics in Australasia
- ☐ Majority of revenues from defensive consumer end-use products



- ☐ Growing in contract manufacturing and materials handling
- ☐ Generating good cash flow





## Pact Group – Factors impacting performance



☐ Higher electricity prices

☐ Higher input prices

□Increased competition

□ Contract manufacturing issues







## Pact Group – Why are we still holding/adding to?



■ New focused CEO

□ Input prices stabilising



☐PE of 10x earnings







## Mayne Pharma



- ☐ Global diversified pharmaceutical company with three key divisions
- ☐ Expertise in dermatology products & anti-fungals
- ☐ Large 150+ person branded drug sales force
- ☐ New manufacturing plant & \$50m annual R&D budget
- Experienced Management & Board



## Mayne Pharma – Factors influencing performance



☐ Number of US generic wholesalers merged (5 down to 3)

➤ Generic price deflation 20%+

☐ Generics division profits fell down heavily (>30%)



## Mayne Pharma – why we have increased our holding



- Quality of earnings mix is improving
- > FY21 GP: Branded drugs 40%, Generics 40%, Contract services 20%
- ☐ Branded drugs is forecast to grow ~75% over the next 3 years due to Tolsura
- ☐ Contract services division continues grow @ double digit rates
- ☐ Generic pricing will stabilise, as the industry rationalises
- ☐ Forecast FY21 PE ~12x (adj. goodwill)




# Top 10 stocks

Top 10 holdings		
Amcor	4.6%	
Aurizon	4.5%	
Crown Resorts	4.4%	
Sonic Healthcare	4.0%	
Caltex	3.8%	
Steadfast	3.5%	
Tabcorp	3.4%	
GWA	3.0%	
Bank of Queensland	3.0%	
Orica	2.9%	




# **QVE Sector positioning**





## QVE Portfolio as at 30 September 2019





## Portfolio construction

- ☐ Portfolios underpinned by quality industrial companies
- ☐ Discipline required on valuations
- Sustainable earnings from a diverse range of sectors
- Solid and consistent dividend levels

☐ Cash ready to take advantages of a pull back



## How to be best positioned for stockmarket corrections


☐ Hold good quality stocks whose valuation makes sense

□ Diversified portfolio

☐ Hold healthy portion of cash




## **Historical NTA**



Past performance is not a reliable indicator of future performance




## NTA: Premium v Discount as at August 2019





## LIC example: Argo Investments

## Share Price (Premium / Discount) to NTA





# 20 lessons from 20 years of quality and value investing



www.iml.com.au/20-lessons

## Why hold QVE?

More diverse investment opportunity set

☐ Investors typically underweight in the ex 20 segment

- Less researched opportunities
- ☐ Good yields on offer

☐ IML has a long record of significant value add in this segment....



## The role of a 'Value Manager' in a portfolio

Expectations of a 'Value Manager'	IML
Reasonable capital growth over time	✓
Resilience in falling markets	$\checkmark$
Lower volatility	✓
Consistent income	✓
Tax effective*	✓

Equities Ltd.

#### **DISCLAIMER**

- Investors Mutual Limited AFSL 229988 (IML) has prepared the information in this presentation, as the Investment manager for, and on behalf of, QV Equities Limited ACN 169 154 858 (QVE). This presentation has been prepared for the purposes of providing general information only and does not constitute personal financial product or investment advice as it does not take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation in making an investment decision but must make its own assessment of QVE, conduct its own investigations and analysis, and seek independent financial, taxation and legal advice. Past performance is not a reliable indicator of future performance.
- □ IML, QVE, their directors, employees and consultants do not warrant the accuracy, reliability or completeness of information contained in the presentation and, to the extent permitted by law, accept no responsibility for any loss or damage arising in any way (whether arising in contract, or tort or negligence or otherwise) from any representation, error or omission in the information or from any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this material or any other person. The information provided within the presentation is not intended to be a complete description of matters described.
- Usage and linking to the QVE presentation is at the users own risk. QVE will not be liable for any loss or damage from any cause (including negligence) to a users system or presentation, or to people linking to QVE from a users presentation, caused by or in connection with the use of or a link to the QVE presentation. Any such loss or damage is at the responsibility of the user. QVE advises users to take their own precautions in relation to protecting their system or presentation from viruses or malfunction.
- Copyright in the information contained in this presentation is owned by QVE. Use of this information or reproduction of it in any form is allowed for personal use only. Without limiting the generality of the foregoing, QVE does not permit reproductions of its material in other presentations in conjunction with advertising, trademarks, logos on material of other financial planners or competitors without the express written permission of QVE.
- All currency references are references to Australian dollars (unless otherwise specified) and any reference to law is to the law of Australia.
- All estimates are made on a reasonable basis and are not a guarantee of actual outcomes or performance.

